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Available online xxxxBackground: Relapse of serious mental illness (psychotic and bipolar disorders; SMI) in the postpartum period is
potentially devastating for mother and baby. There is limited evidence on whether medication in the perinatal
period is protective against postpartum relapse for women with SMI particularly non-affective psychoses. We
aimed to investigate risk factors for postpartum relapse, particularly the potential prophylactic effects ofmedica-
tion.
Methods: Using an anonymised resource of comprehensive electronic secondary mental health care records
linked with maternity data, women with history of SMI who gave birth from 2007 to 2011 were identiﬁed.
Relapse was deﬁned as admission to acute care in the ﬁrst 3 months postpartum. Womenwho were exposed to
regular medication were compared with womenwho were unexposed. Data were analysed by pregnancy using
random effects models to account for repeated measures in women who had more than one pregnancy in the
study period.
Results: There were 452 full term pregnancies, of which 128 (28.3%) were associated with relapse in the ﬁrst
3 months postpartum, with recent relapse an independent predictor (aOR; 95% CI:1.30–2.27). There was no ev-
idence of a prophylactic effect of medication (crude OR= 0.65; 0.34–1.25) (aOR= 0.99; 0.54–1.83), in women
with non-affective or affective psychoses (interaction test p = 0.453).
Conclusions:Recent relapse increases the risk of relapse in the postpartum period sowomenwith severe illnesses
with a recent history of relapse should be warned pre-conception about the high risk of relapse.
The lack of evidence of a protective impact of medication prophylaxis may reﬂect confounding by indication.
© 2018 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Cohort1. Introduction
Relapse of serious mental illness (psychotic and bipolar disorders)
around childbirth is potentially devastating. The acute onset of psycho-
ses immediately following childbirth are among the most severe disor-
ders seen in psychiatry and may be associated with adverse
consequences for the woman, her family and the capacity to parent
(Howard, 2005), as well as (rarely) lead to suicide and/or infanticide.
UK and Australian Conﬁdential Enquiries highlight psychiatric illness
as a leading contributor to maternal deaths (Austin et al., 2007;
Cantwell et al., 2011). Research has established that women with bipo-
lar disorder have high risk of relapse postpartum, with reported esti-
mates ranging from 17 to 75% (Di Florio et al., 2013; Doyle et al.,
2011; Maina et al., 2014; Wesseloo et al., 2015). The ﬁrst few weeks
postpartum are the time of highest risk (Munk-Olsen et al., 2009)andal Medicine, BRC Nucleus, PO92
pigny Park, London SE5 8AF, UK.
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(Jones and Craddock, 2001, 2002), previous perinatal episodes
(Chaudron and Pies, 2003) and not living with the father of the child
have been highlighted as potential risk factors (Nager et al., 2005).
Less research has been carried out in women with schizophrenia and
other non-affective psychoses. Two large registry studies estimated
16–22% rates of readmission in the ﬁrst 3 months postpartum
(Harlow et al., 2007; Munk-Olsen et al., 2009) and more recently
19.1% for women with schizophrenia in the ﬁrst year postpartum
(Rochon-Terry et al., 2016). Previous inpatient admissions, the number
and recency of previous admissions and admission during pregnancy
have been associatedwith postpartum readmission in womenwith his-
tory of psychotic and bipolar disorders (Harlow et al., 2007; Munk-
Olsen et al., 2009).
A recent systematic review reported that inwomenwith bipolar dis-
order, postpartum relapse rates were signiﬁcantly higher among those
who were medication free during pregnancy (66%, 95% CI = 57, 75)
than those exposed to medication (23%, 95% CI = 14, 37) (Wesseloo
et al., 2015). However, in observational research it is very difﬁcult to dis-
entangle characteristics of the psychiatric illness from effects ofthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
onths postpartum in women with history of serious mental illness,
2 C.L. Taylor et al. / Schizophrenia Research xxx (2018) xxx–xxxmedication andprevious studies looking atmedication and relapse have
been limited in the potential confounding factors adjusted for. There has
been no research looking at medication and postpartum relapse in
women with schizophrenia.
We aimed to investigate risk factors for relapse of SMI (affective psy-
chosis and non-affective psychoses) using a novel informatics case reg-
ister of women in secondary mental health care in south London and
examine whether medication exposure in the third trimester and
early postpartum prevented relapse. We hypothesized that women on
nomedication in the third trimester of pregnancy and/or early postpar-
tumwould be at greater risk of postpartum relapse thanwomen on reg-
ular medication in the third trimester and that women with history of
affective disorders would be more likely to relapse than women with
non-affective disorders.
2. Methods
2.1. Study design
Historical cohort study using secondary mental health care data
linked to national maternity data.
2.2. Data source
The South London & Maudsley (SLAM) NHS trust provides second-
ary mental health care and some tertiary services including a perinatal
service to a geographical catchment area of four London boroughs and
a source population of around 1.2 million residents. Electronic records
date back as far as 1999 and all clinical records have been fully electronic
since 2006. The NIHR Biomedical Research Centre Clinical Record Inter-
active Search (CRIS) is an anonymised version of these used for re-
search. There are about 250,000 patient records on the system and
data can be retrieved from structured ﬁelds and free text (Perera et al.,
2016). Much of the information is in free text and a number of natural
language processing applications have been developed using General
Architecture for Text Engineering (GATE) software, which allow struc-
tured data to be retrieved from free text taking into account the linguis-
tic context of key search terms (Cunninghamet al., 2013). CRIS has been
approved as a research resource by Oxfordshire Research Ethics Com-
mittee C (08/H0606/71+ 5) and is linked to other sources of secondary
data including Hospital Episode Statistics (HES). This is national statisti-
cal data for hospital admissions in England and includes maternity data
(NHS Digital, 2016).
2.3. Study cohort
Methods to identify the study cohort are described elsewhere
(Taylor et al., 2015).We includedwomenwith history of SMIwhodeliv-
ered babies from 2007 to 2011. CRIS was used to identify women with
SMI and linked maternity HES to identify delivery of a baby (live birth
or still birth over 24 weeks). Women with history of SMI before the
pregnancy were included based on ICD-10 diagnoses F20, F22, F23,
F25, F28, F29 (schizophrenia and related disorders, schizoaffective dis-
orders and delusional disorders), F30, F31 (mania and bipolar affective
disorders), F32.3, F33.3 (psychotic depression), or F53.1 (puerperal psy-
chosis) from structured ﬁelds or a GATE diagnosis application. Where
clear diagnostic history could not be ascertained or there was no avail-
able diagnostic data, notes were read by a researcher to determine the
patient's psychiatric history from clinical notes. Women had to be
under SLaM care at any point from 6 months before to 6 weeks after
the HES delivery episode so that details of their mental health care dur-
ing the perinatal period would be recorded. We excluded women with
above diagnoses dated for the ﬁrst time during or after pregnancy and
women with insufﬁcient data to establish medication use. Delivery
date was ascertained from the last date of the HES episode or
subtracting postnatal days of stay. Fig. 1 shows details of cohort,Please cite this article as: Taylor, C.L., et al., Relapse in the ﬁrst three m
Schizophr. Res. (2018), https://doi.org/10.1016/j.schres.2018.07.037timelines and exclusions. We later added women who delivered babies
from 2012 to 31st March 2013 when more HES data became available.
Not all data were available for these extra pregnancies.
2.4. Measures
Relapse of SMI in ﬁrst 3 months postpartum: admission to inpatient
care or referral for home treatment/crisis resolution (services offered in
the UK in an acute mental health crisis as an alternative to inpatient ad-
mission involving frequent (usually daily) home visits (Johnson et al.,
2008). Data were extracted from structured ﬁelds in CRIS, supple-
mented by HES data for admissions to inpatient mental health wards
outside SLaM. Admissions to the SLaM mother and baby unit can
occur for acute psychiatric illness, prophylaxis or parenting assess-
ments. Admissions for acute illness only were included.
Diagnosis at baseline, recorded just prior or at the start of pregnancy
was categorised into non-affective (schizophrenia, delusional disorders,
acute and transient psychoses, schizoaffective disorders, other non-
organic psychoses) and affective SMI (bipolar affective disorder, psy-
chotic depression and previous postpartum psychosis.). We also
redeﬁned acute and transient psychoses, schizoaffective disorders,
other non-organic psychoses as possible affective psychoses. Unless
otherwise stated, the original categorisation is used throughout.
Medication exposure: Regular antipsychotic,mood stabiliser or anti-
depressant exposure in third trimester and ﬁrst week postpartum was
ascertained using a GATE application supplemented by manual text
searches. Stops, starts and switches in regular antipsychotics, mood
stabilisers and antidepressants were noted. Possible non-exposure
was categorised if therewas awritten concern about adherence indicat-
ing a possibility of no exposure. Starting a prophylactic medication was
recorded in 3rd trimester or 1st week postpartum if a woman started a
regular medication for reasons other than psychiatric symptoms. The
GATE medication application has been validated for a number of anti-
psychotic medications with precision statistics ranging from 0.93–0.7
and recall from 0.57–0.92. Due to the time windows of medication re-
quired, documents identiﬁed by GATEwere recalled and read manually
for coding by researchers in order to establish amore ‘gold standard’ re-
cording of medication in pregnancy. Two researchers rated medication
exposure and a consecutive 22 caseswere independently rated for iden-
tiﬁcation of antipsychotic, mood stabiliser and antidepressant with
agreement of 85%, 100% and 100% respectively for the third trimester
of pregnancy.
2.4.1. Covariates
Ethnicity was extracted from structured data and categorised into
‘Black African/Caribbean/other’, ‘White British/other’, and ‘Mixed,
Asian, other/not stated’. Area-level deprivation score was extracted
closest in date to beginning of pregnancy – a summary socioeconomic
measure derived fromUKCensus data (2007) (Noble et al., 2007).Man-
ual searches using piloted terms were carried out to establish children
prior to index pregnancy, relationship status in pregnancy, history of
childhood and domestic abuse (physical, sexual, emotional, and coer-
cive) before or during pregnancy, smoking in pregnancy and family his-
tory of psychosis. We recorded and analysed positive hits only. If
information is missing in the clinical text it is impossible to tell whether
it is ‘negative’ or just not recorded. There was a very high proportion of
missing information and information on ‘negative’ hits were not com-
monly reported. Therefore ‘negative hits’ and missing were combined.
Covariates collected using manual free text searches were only for the
original 2007–2011 cohort, not for pregnancies ending 2012–13.
Acute episodes were recorded if there was an admission to acute
care (inpatient or home treatment) extracted using CRIS, supplemented
with HES to identify admissions to inpatient care outside SLaM. We re-
corded acute psychiatric episodes during pregnancy and in the 2 years
before. A spell of acute care in the 2 years before pregnancywas deﬁned
as a period of admission to acutemental health care where there was atonths postpartum in women with history of serious mental illness,
Fig. 1. Diagram to show how the cohort was established and exposure variables collected.
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was coded ‘pregnancy’ if there was an admission during pregnancy and
‘1 year’ if there was an admission in the year before pregnancy but not
during pregnancy or ‘2 year’ if the beginning of the most recent spell
fell in the 2 years before the beginning of pregnancy. Fig. 1 displays
time relationships of exposures and pregnancies.
Manual review of case notes was carried out to ascertain recorded
smoking, and alcohol and drug use in pregnancy, supplemented by a
substance misuse diagnosis within the previous 2 years. The highest
total adjustedHealth of theNationOutcomeScale (HoNOS) score, a rou-
tinely collected 12 itemmeasure in UK mental health services of health
and social functioning of people with severe mental illness, recorded in
the 2 years prior to delivery was also extracted (Wing et al., 1998).
These data were only available for 2007–2011 pregnancies.
2.5. Data analysis
Data were analysed using STATA 12. Period prevalence of relapse in
the ﬁrst 3 months postpartum was calculated by pregnancy. Incidence
of newly occurring relapseswere then calculated excluding pregnancies
where an acute admission occurred during pregnancy. Estimates were
ascertained for the whole sample and separately for 1, 2 and 3 months
postpartum and stratiﬁed by affective and non-affective SMI group.
We also re-categorised possible affective disorders (schizoaffective dis-
order, acute and transient psychosis and psychosis NOS) in the affective
group and then reported separately by 7 separate ICD-10 diagnoses at
baseline (i.e. diagnosis closest to or at the start of the index pregnancy).
To account for repeated measures for women with more than one
pregnancy in the cohort, random effects logistic regression were used
to investigate crude associations between relapse and the twomain ex-
posures - and medication exposure and baseline diagnostic group. ThePlease cite this article as: Taylor, C.L., et al., Relapse in the ﬁrst three m
Schizophr. Res. (2018), https://doi.org/10.1016/j.schres.2018.07.037same method was used to calculate associations between covariates
and relapse, both including and excluding pregnancies where an acute
admission occurred.
Multivariable analyses assessed association with medication in 3rd
trimester and ﬁrst week postpartum and relapse. Covariates were
added as a two-stage process. The model was ﬁrst adjusted for age
and ethnicity and then other covariates were added whichwere associ-
ated with relapse at p ≤ 0.2 (Bursac et al., 2008). To avoid collinearity,
we used only ‘recency of admission’ (during pregnancy, 1 year or
2 years before) in themain analysis as it included adjustment for admis-
sion in pregnancy.Medication exposurewas deﬁned as exposure to reg-
ular antipsychotic, mood stabiliser and or antidepressant throughout.
We also ran bivariate and multivariable analyses including pregnancies
ending in 2012–2013 using covariates available including medication
and those extracted from structured data.
Hypothesis driven interaction tests using the likelihood ratio were
carried out. Given that women on no medication may be either more
non-compliant or more psychiatrically stable, we ran a likelihood ratio
test for the interaction of psychiatric stability (women who had not
been admitted in the 2 years before pregnancy) and medication on re-
lapse. Bipolar disorder has been associated with rapidly occurring post-
partum relapse whereas non-affective diagnoses may represent a more
chronic risk of relapse (Munk-Olsen et al., 2009) so we also ran a hy-
pothesis test for the interaction of medication and diagnosis (affective
vs non-affective) on relapse. Finally as domestic abuse may impact on
symptomatology inwomenwith SMI (Khalifeh et al., 2015)we rana hy-
pothesis driven interaction test for domestic abuse and medication.
Risk of relapse at 3 months postpartum in the affective and non-
affective group were then compared using random effects logistic re-
gression, adjusted for confounders. We also ran the model re-
categorising possible affective disorders in the affective group andonths postpartum in women with history of serious mental illness,
4 C.L. Taylor et al. / Schizophrenia Research xxx (2018) xxx–xxxcomparing schizophrenia and bipolar disorder only, in order to draw a
comparison with literature looking only at bipolar disorder and
schizophrenia.
2.5.1. Sensitivity analyses
Research has shown that admission in pregnancy is a predictor of
postpartum relapse. However, admission, particularly if occurring in
late pregnancymay be part of the same relapse.We therefore ran sensi-
tivity analyses excluding pregnancies where admission occurred during
pregnancy, both for comparison of relapse risk in the affective and non-
affective groups, and analysis of medication and relapse. We used the
same modelling strategy, but instead of using ‘recency of admission’,
we adjusted for ‘admission in 2 years before pregnancy’ as there were
fewer cases in these analyses and this measure of previous hospital ad-
mission was more strongly associated in the bivariate analyses exclud-
ing pregnancies with admissions. We also ran sensitivity analyses
moving those who started a medication in the ﬁrst week postpartum
(for reasons other than emerging psychiatric symptoms) to themedica-
tion exposed group. To address possible misclassiﬁcation of medication
exposure, a sensitivity analysis excludedwomen coded as possibly non-
adherent.
Due to research showing bipolar disorder to be associated with rap-
idly occurring postpartum relapse, further sensitivity analyseswere car-
ried out including relapses occurring in the ﬁrst month postpartum
only. These analyses were run including and excluding pregnancies
with an admission during pregnancy and comparing affective and
non-affective groups and schizophrenia and bipolar groups.
3. Results
3.1. Sample characteristics
The cohort included 452 pregnancies in 396 women (Fig. 1); 47
women had more than one pregnancy in the study period including 7
with more than two. At baseline, 200 (50.5%) had a diagnosis of non-
affective SMI: 110 (27.8%) with schizophrenia or delusional disorder,
26 (6.6%) a schizoaffective diagnosis and 64 (16.2%) other non-
affective diagnoses. The other 196 (49.5%) women had an affective
SMI diagnosis including bipolar affective disorder (144 women,
36.4%), depressive psychosis (45 women, 11.4%) and 7 (1.8%) a history
of postpartum psychosis only. Comorbid diagnoses between 9 months
and 2 years before delivery included 18 (4.6%) women with substance
use disorders, 9 (2.3%) with personality disorder diagnoses, 12 (3.1%)
with anxiety disorders, 5 (1.3%) with learning difﬁculties and b 5 with
other diagnoses including eating disorders, conduct disorders and epi-
lepsy. There were 17 pregnancies with missing data for deprivation
score and 186 pregnancies had missing HoNOS scores. Including preg-
nancies ending 2012–2013, there were 570 pregnancies in the cohort,
277 in the affective SMI group and 293 in the non–affective SMI group.
3.2. Medication exposures
In 3rd trimester, 274 (60.6%) pregnancies were exposed to regular
medication; 234 (51.8%) to an antipsychotic, 30 (6.6%) to a mood stabi-
liser (19 (4.2%) to lithium) and 92 (20.35%) to an antidepressant. This
includes 72 (15.9%) exposed to two medications and 18 (4.0%) to
more than two. Five pregnancies had records of ‘possible non-
exposure’ in the 3rd trimester. Of these 239 (87.2%) were also taking
medication in the 2nd trimester and 88.7% (243) were also exposed in
1st trimester.
Of the 178 pregnancies unexposed to medication in 3rd trimes-
ter, 90.5% (n = 161) were also unexposed in 2nd trimester and
62.9% (n = 112) unexposed in the 1st trimester.
In 35 (7.7%) pregnancies there was initiation of regular medication
(antipsychotic, mood stabiliser or antidepressant) in the 3rd trimester
or 1st week postpartum for reasons other than emerging psychiatricPlease cite this article as: Taylor, C.L., et al., Relapse in the ﬁrst three m
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Of these also, 27 started a medication in the 1st week postpartum, 16
were not on medication in the 3rd trimester and 11 were.
By diagnosis (Suppl. Table 1), prevalence of medication exposure
was a little higher in the non-affective group and schizophrenia group
than the affective group. Themost commonmedication groupwas anti-
psychotics and women with schizophrenia were about 50% more com-
monly exposed thanwomenwith bipolar disorder. Howevermore (2–5
fold) of the bipolar group were on mood stabilisers compared with the
non-affective groups. For antidepressants, exposure was around twice
as common in the affective than non-affective groups.
3.3. Relapse in 3 months postpartum
There were 128 (28.3%) relapses during the ﬁrst 3 months postpar-
tum (see Fig. 2 for relapses by month and diagnosis). Most (71.1%)
occurred in the ﬁrst month and by the third month it was predomi-
nantly women with schizophrenia who relapsed. 89 (19.7%) pregnan-
cies involved an admission to acute psychiatric care. Of these, 42
(47.2%) were also admitted in the ﬁrst 3 months postpartum. For the
363 pregnancies without relapse during pregnancy, most postpartum
relapses occurred in the ﬁrst month. Women with broadly deﬁned af-
fective psychoses (i.e. affective psychoses, acute and transient,
schizoaffective and psychosis NOS) were more likely to relapse earlier
in the postpartum period. Including the pregnancies from 2012 to
2013, there were 151 (26.5%) relapses during the ﬁrst 3 months post-
partum (25.3% affective group, 27.7% non-affective). Excluding those
who relapsed in pregnancy, there were 465 pregnancies, 105 (22.6%)
with relapses postpartum (22.0% affective group, 23.2% non-affective).
3.4. Predictors of relapse in postpartum
Table 1 shows associations between covariates and relapse in the
three months postpartum, both for the whole sample and excluding
pregnancieswith acute admission. Smoking and indicators of admission
historywere associatedwith relapse. Relapse in pregnancywas a strong
predictor of relapse postpartum (OR: 5.09). Excluding those who re-
lapsed in pregnancy, smoking, recency of admission and number of ad-
missions in the two years before pregnancy were associated with
relapse. Supplementary Table 2 shows analyses including 2012–2013
ending pregnancies. Results did not differ meaningfully.
3.4.1. Multivariable analysis
There was no association between medication exposure in 3rd tri-
mester and relapse postpartum (Table 2). Stratifying by baseline diag-
nosis, the non-affective unexposed group had higher odds of relapse
than those taking medication and the affective unexposed had lower
odds of relapse than those onmedication, but thesewere not signiﬁcant.
Likelihood ratio tests showed no evidence of an interaction between
medication and baseline diagnosis on relapse (unadjusted chi2 =
0.20, p = 0.657, fully adjusted chi2 = 0.56, p = 0.453), or between ad-
mission in the 2 years before pregnancy andmedication on relapse (un-
adjusted chi2= 0.01, p= 0.929, fully adjusted chi2= 0.16, p= 0.685).
Tests for interaction between history of domestic violence and medica-
tion (unadjusted chi2=1.81, p=0.180, fully adjusted chi2=1.56, p=
0.212) and history of child abuse and medication (unadjusted chi2 =
0.69, p = 0.405, fully adjusted chi2 = 0.65, p = 0.421) on relapse sug-
gested little evidence. Supplementary Table 3 shows unadjusted and
fully adjusted odds of association with relapse for each covariate sepa-
rately. In the fully adjusted model, recency of last episode was associ-
ated with relapse in 3 months postpartum. Table 3 compared relapse
in the non-affective and affective groups. The non-affective groups
had higher odds of relapse than the affective group, but ﬁndings were
not signiﬁcant and were attenuated on adjusting for confounders.
When the affective/non-affective groups were re-categorised, the odds
ratio of relapse in schizophrenia compared with the other diagnosesonths postpartum in women with history of serious mental illness,
Fig. 2. Postpartum relapse by diagnosis at the beginning of pregnancy (numbers reﬂect pregnancy episodes rather than number of women).
5C.L. Taylor et al. / Schizophrenia Research xxx (2018) xxx–xxxwas greater, and restricting to schizophrenia and bipolar disorder only,
resulted in greater odds of relapse for schizophrenia compared with bi-
polar disorder although these differences were not statistically signiﬁ-
cant. Therefore, different ways of categorising the affective/non-
affective group did not change our ﬁndings.
3.4.2. Sensitivity analyses
Although we did not ﬁnd an association between medication in the
3rd trimester and relapse, excluding those who relapsed in pregnancy
from the multivariable analyses further attenuated the ﬁndings such
that odds ratios were closer to 1 and there was less difference between
themedicated and unmedicated groups.Moving thosewho started pro-
phylactic medication in the ﬁrst week postpartum into the medication
exposed group meant that the unexposed group were slightly more
likely to relapse than the exposed group, but this did not change overall
ﬁndings. Excluding those recorded as possibly non-exposed made little
difference. There was a slight but non-signiﬁcant attenuation in the as-
sociationwhen excluding pregnancieswhere therewas an admission to
acute care in pregnancy (Table 2). Sensitivity analysis moving those
who started medication in the ﬁrst week postpartum increased the as-
sociation slightly (making 'no medication' appear more protective)
but non-signiﬁcantly. Removing possible non-exposure to address mis-
classiﬁcation of medication exposure made little difference to the
ﬁndings.
For those who relapsed in ﬁrst month postpartum (Table 4) ﬁndings
were the same, although when stratiﬁed by SMI group, odds of relapse
in the non-affective group were markedly attenuated compared with
the full sample such that they went from having higher odds of relapse
compared with the group on medication to lower odds of relapse.Please cite this article as: Taylor, C.L., et al., Relapse in the ﬁrst three m
Schizophr. Res. (2018), https://doi.org/10.1016/j.schres.2018.07.037However, ﬁndingswere not signiﬁcant. Table 3 shows comparison of af-
fective and non-affective disorders for pregnancies with relapses in the
ﬁrst month postpartum. Findings were the same as the full sample but
odds were slightly attenuated.
4. Discussion
4.1. Main ﬁndings
In 389womenwith history of SMI and 452 pregnancies from2007 to
2011, there were 28.3%with a relapse in the ﬁrst threemonths postpar-
tum. After excluding pregnancies in which an acute psychiatric admis-
sion occurred, 23.7% had a relapse postpartum. Most were in the ﬁrst
month. Previous research has yielded a very wide range of estimates
of risk of postpartum relapse particularly for womenwith bipolar disor-
der. However our ﬁndings are consistent with a recentmeta-analysis of
postpartum relapse in women with bipolar affective disorder and post-
partum psychosis (Wesseloo et al., 2015). A recent population registry
reported 19% (Rochon-Terry et al., 2016) were hospitalised in the ﬁrst
year postpartum in women with schizophrenia and found the ﬁrst
three months was the time of highest risk.
There was no association between medication exposure in preg-
nancy and relapse postpartum and sensitivity analysis including post-
partum prophylaxis in the medication exposed group did not alter the
ﬁndings. In contrast to our ﬁndings other literature has reported pre-
ventive effects of medication in pregnancy and the immediate postpar-
tum on postpartum relapse. A systematic review reported pooled risk
estimates of 23% in a total of 60 women with bipolar disorder exposed
to medication in pregnancy compared with 66% in a total of 385onths postpartum in women with history of serious mental illness,
Table 1
association of baseline diagnostic group, medication and covariates with relapse in ﬁrst 3 months postpartum.
Covariates All pregnancies (N = 452) Excluding those who relapsed in pregnancy
(N = 363)
N % relapse OR (CI) P N % relapse OR (CI) P
No medication in 3rd trimester 178 24.7 0.65 (0.34,1.25) 0.199 168 23.8 1.00 (0.48,2.11) 0.994
Exposure to regular medication 3rd tri 274 30.7 Ref 195 23.6 Ref
No medication in 3rd trimester 178 24.7 0.53 (0.27,1.03) 0.062 168 23.8 1.00 (0.48,2.11) 0.994
Exposure to regular medication 3rd tri or postpartum prophylaxis 274 30.7 Ref 195 23.6 Ref
Baseline diagnosis
Affective 218 25.7 Ref 190 22.1 Ref
Non affective 234 30.8 1.41 (0.76,2.60) 0.234 173 25.4 1.33 (0.62,2.84) 0.463
Baseline diagnosis
Affective (incl schizoaffective) 248 26.6 Ref 210 22.4 Ref
Non affective 204 29.9 1.28 (0.70,2.37) 0.422 153 25.5 1.32 (0.61,2.85) 0.485
Ethnicity
White 220 29.1 Ref 163 23.3 Ref
Black 148 28.4 1.09 (0.54,2.21) 0.815 135 26.7 0.73 (0.31,1.72) 0.470
Asian/other 84 26.2 0.66 (0.25,1.75) 0.402 65 18.5 0.43 (0.13,1.48) 0.183
Deprivation score, median (range) 435 34.9
(4.8–61.5)
1.00(0.98,1.03) 0.745 349 34.9
(4.8–61.5)
1.00(0.96,1.03) 0.802
Age, mean (SD) 452 31.9 (6.0) 1.00 (0.96,1.06) 0.858 363 32.1 (6.0) 1.03 (0.96,1.03) 0.368
Partner during pregnancy 315 28.6 1.04 (0.54,2.00) 0.896 260 25.0 1.50 (0.63,3.59) 0.358
No partner during pregnancy 137 27.7 Ref 103 20.4 Ref
Child abuse 93 36.6 1.80 (0.85,3.78) 0.123⁎ 74 29.7 1.69 (0.67,4.27) 0.269
No child abuse 359 26.2 Ref 289 22.2 Ref
DV before or during pregnancy 170 32.4 1.37 (0.74,2.53) 0.310 129 25.6 1.13 (0.52,2.45) 0.764
DV not reported 282 25.9 Ref 234 22.7 Ref
Psychosis in 1st degree relatives 67 31.3 1.07 (0.45,2.53) 0.886 51 29.4 1.48 (0.53,4.15) 0.454
None recorded 385 27.5 Ref 312 22.8 Ref
Primiparous 187 29.4 1.24 (0.67,2.28) 0.494 146 24.0 1.10 (0.52,2.32) 0.805
Not primiparous 265 27.6 Ref 217 23.5 Ref
Preterm 68 19.1 0.47 (0.19,1.17) 0.105⁎ 62 17.7 0.59 (0.21,1.64) 0.312
Full term 384 30.0 Ref 301 24.9 Ref
Smoking in pregnancy 85 41.2 2.52 (1.22,5.19) 0.013⁎ 49 38.9 3.30 (1.12,9.70) 0.030⁎
No smoking in pregnancy 367 25.3 Ref 314 21.4 Ref
Harmful substance use 111 26.1 0.85 (0.42,1.69) 0.637 74 24.9 0.61 (0.23,1.59) 0.310
Not recorded 341 29.0 Ref 289 18.9 Ref
Admission 2 years before pregnancy 191 35.6 2.00 (1.16,3.47) 0.013⁎ 136 30.2 1.92 (0.95,3.9) 0.068⁎
No admission 2 years before 261 23.0 Ref 227 19.8 Ref
Admissions (N) before pregnancy
0 261 23.0 Ref 227 19.8 Ref
1 121 28.9 1.41 (0.76,2.59) 0.274 94 25.5 1.41 (0.66,3.03) 0.378
2 42 45.2 2.94 (1.23,7.03) 0.015⁎ 42 40.5 3.50 (1.24,9.89) 0.018⁎
N/=3 28 50.0 4.27 (1.44,12.68) 0.009⁎ – – – –
Trend 452 28.3 1.63 (1.21,2.20) 0.001⁎ 363 23.7 1.75 (1.09,2.83) 0.021⁎
Time since last episode
None preg/2 y before 227 19.8 Ref 227 19.8 Ref
2 years before 70 27.1 1.65 (0.70,3.89) 0.255 70 27.1 1.66 (0.70,3.90) 0.248
1 year before 66 33.3 2.15 (0.93,4.99) 0.073⁎ 66 33.3 2.19 (0.95,5.03) 0.066⁎
Pregnancy 89 47.2 5.96 (2.24,15.86) b0.001⁎ N/A N/A N/A N/A
Trend 452 28.3 1.71 (1.30,2.27) b0.001⁎ 363 23.7 1.49 (1.00,2.24) b0.053⁎
Self-harm pregnancy/2 years before 86 30.2 1.23 (0.57,2.62) 0.597 46 15.2 0.33 (0.08,1.46) 0.146
No self-harm reported 355 27.9 Ref 317 24.9 Ref
Highest HoNOS 6 2 years before delivery, median (range) 244 12 (0–29) 0.98 (0.90,1.06) 0.553 186 11 (0–29) 0.97 (0.90,1.04) 0.342
⁎ p b 0.2.
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tion of the ‘nomedication’ group came from one tertiary referral centre
in a single clinical study of 276 medication free women (with a relapse
rate of 75%), which may include women with particularly severe disor-
ders; moreover, relapse was measured by medical note review from a
clinician. There was also no adjustment in this meta-analysis for poten-
tial confounders. Previous research investigating medication in preg-
nancy and postpartum relapse in women with bipolar disorder has
deﬁned exposure across the whole of pregnancy (Bergink et al., 2012;
Wesseloo et al., 2015). We instead focused on the third trimester as
other research (Toh et al., 2013; Viguera et al., 2007) including our
own work (Taylor et al., 2015) has shown that many women change
medications in early pregnancy – over 40% of women in this cohort. In
this cohort we have also found that women on no medication at the
start of pregnancy tended to relapse early in pregnancy (Taylor et al.,Please cite this article as: Taylor, C.L., et al., Relapse in the ﬁrst three m
Schizophr. Res. (2018), https://doi.org/10.1016/j.schres.2018.07.0372018), following which they are likely be commenced on medication.
Given so many changes in medication in early pregnancy and consis-
tency in medication groups particularly across 2nd and 3rd trimesters
we thought later pregnancy would capture women who have been
stabilised on medication following earlier changes coinciding with the
commencement of pregnancy or secondary to relapse, although did
not envisage that ﬁndings would be vastly different from those using
data measuring exposure across the whole of pregnancy. However, it
is also contrary to clinical observations that medication in pregnancy
was not shown to be preventive for relapse. Our results might well
reﬂect confounding by indication. Given that we used data from
secondary mental health care it may be that women most at risk of
relapse were managed well by secondary care services on medication
than those who were less engaged. The groups were likely heteroge-
neous and although we attempted to look at some of the heterogeneityonths postpartum in women with history of serious mental illness,
Table 2
Multivariable analyses of medication exposure and postpartum relapse in the ﬁrst 3 months postpartum comparing those exposed to medication in 3rd trimester/ﬁrst week postpartum
(reference group) with those not exposed to medication.
All pregnancies Whole sample (n = 452) Moving starters (n = 452) Excluding possible non-exposure (n = 447)
OR (CI), p OR (CI), p OR (CI), p
Unadjusted association 0.65 (0.34,1.25), 0.199 0.53 (0.27,1.03), 0.062 0.65 (0.33,1.28), 0.211
Model 1* 0.63 (0.32,1.25), 0.189 0.50 (0.25,1.03), 0.059 0.63 (0.31,1.28), 0.202
Model 2† 0.99 (0.54,1.83), 0.975 0.76 (0.41,1.41), 0.380 0.98 (0.52,1.84), 0.943
Model 2
affective group
0.73 (0.22,2.48), 0.614
n= 218
0.40 (0.09,1.68), 0.208 n = 218 0.73 (0.22,2.48), 0.614 n = 218
Model 2
non-affective group
1.25 (0.63,2.45), 0.525 n= 234 1.18 (0.61,2.30), 0.616 n = 234 1.21 (0.61,2.38), 0.583 n = 229
Model 2
admitted 2 yrs before
1.01 (0.37,2.89), 0.981N = 191 0.64 (0.22,1.89), 0.417
N = 191
0.99 (0.36,2.74), 0.981
N = 189
Model 2
not admitted 2 yrs before
1.22 (0.18,8.29), 0.842
N = 261
0.71 (0.10,4.90), 0.728
N = 261
1.26 (0.19,8.29),0.810
N = 258
Model 2
History of DV
0.59 (0.18,1.99), 0.398
N = 170
0.33 (0.09,1.21), 0.095
N = 170
0.58 (0.16,2.08), 0.402
N = 168
Model 2
no history of DV
1.23 (0.64,2.35), 0.539
N = 282
1.23 (0.64,2.37),0.540
N = 282
1.23 (0.64,2.37), 0.525
N = 279
Model 2
History of child abuse
1.28 (0.45,3.63), 0.649
N = 93
1.29 (0.46,3.65), 0.632
N = 93
0.89 (0.31,2.51), 0.649
N = 93
Model 2
no history of child abuse
1.10 (0.42,2.90), 0.852
N = 359
0.70 (0.26,1.91), 0.485
N = 359
0.99 (0.32,3.07), 0.991
N = 354
Excluding acute admissions in pregnancy
(n = 363) (n = 363) (n = 361)
Unadjusted 1.00 (0.48,2.11), 0.994 0.81 (0.38,1.73), 0.581 0.98 (0.47,2.07), 0.963
Model 1* 1.07 (0.49,2.35), 0.868 0.83 (0.37,1.84), 0.645 1.05 (0.48,2.31), 0.901
Model 2† 1.05 (0.48,2.29), 0.897 0.93 (0.47,1.85), 0.836 1.17 (0.59,2.30), 0.658
Model 2
Affective group
0.94 (0.36,2.44), 0.894 n= 190 0.72 (0.26,2.00), 0.527 n= 190 0.94 (0.36,2.44), 0.894 n= 190
Model 2
Non-affective group
1.47 (0.69,3.17), 0.320 n= 173 1.29 (0.61,2.74), 0.502 n= 173 1.41 (0.66,3.04), 0.376 n= 171
*Model 1: adjusted for age & ethnicity.
†Model 2: Model 1, plus factors associated at p b 0.2 in Table 1 (preterm birth, history of child abuse, recency of last episode and smoking in pregnancy).
7C.L. Taylor et al. / Schizophrenia Research xxx (2018) xxx–xxxby examining interactions, the different secondary services, levels of
care, severities of illness and engagement with professionals and medi-
cation regimes were not feasibly disentangled in a sample of this size.
No previous work has looked at the impact of medication on relapse
in women with non-affective SMI in the perinatal period. Although dis-
continuation of medication is reported to be a major risk factor for re-
lapse of schizophrenia outside of the perinatal period (Bassett et al.,
1998; Vigod and Ross, 2010) womenwith schizophrenia who are preg-
nant may not be representative of women with schizophrenia in
general.
4.2. Methodological considerations
There are many challenges in evaluating the impact of medication
on prevention of relapse in the perinatal period in this type of observa-
tional study. Pregnancymay alter the pharmaco-kinetics ofmedicationsTable 3
Random effects logistic regression analysis of relapse in ﬁrst three months postpartum and the
non-affective diagnosis at baseline.
Whole sample
(n=452)
Recoding ICD-10 F23, F25, F28, F29 as affec
(n=452)
Non-affective
diagnosis
OR (CI), p OR (CI), p
Unadjusted 1.41 (0.76,2.60), 0.278 1.75 (0.91,3.37), 0.093
Model 1⁎ 1.44 (0.75,2.76), 0.279 1.72 (0.88,3.38), 0.112
Model 2† 1.13 (0.62,2.05), 0.685 1.47 (0.79,2.75), 0.227
1st month relapses
Unadjusted 1.08 (0.55,2.10), 0.823 1.38 (0.68,2.80), 0.373
Model 1⁎ 1.08 (0.54,2.15), 0.837 1.34 (0.65,2.75), 0.423
Model 2† 0.90 (0.46,1.78), 0.764 1.18 (0.58,2.40), 0.644
⁎ Model 1: adjusted for age & ethnicity.
† Model 2: Model 1, plus factors associated at pb0.2 in Table 1 (preterm birth, history of chil
Please cite this article as: Taylor, C.L., et al., Relapse in the ﬁrst three m
Schizophr. Res. (2018), https://doi.org/10.1016/j.schres.2018.07.037including increasing clearance of a number of medications andwewere
not able to deﬁne dose adjustments, therefore at least some women
may have been undertreated in late pregnancy. Clinical records may
under-report adherence and there will be heterogeneity in consistency
of medication use, and illness characteristics – indeed, women on no
medication may be particularly well and stable or chaotic and poorly
engaged with services. However, removing those unwell in pregnancy
(and therefore more likely to relapse postpartum) did not change our
ﬁndings. In agreement with other data (Harlow et al., 2007; Munk-
Olsen et al., 2009), we found that recency of last admission and admis-
sion in the 2 years before pregnancy were associated with postpartum
relapse. Effect moderators not examined previously (e.g. non-affective
psychosis, domestic violence and admission in the 2 years before preg-
nancy) did not suggest a signiﬁcant impact on relapse but the studywas
underpowered to examine these interaction effects. As well as differ-
ences in relapse rates in women exposed and unexposed tomedication,ﬁrst month postpartum, comparing affective diagnosis at baseline (reference group) with
tive Schizophrenia compared with bipolar
(n=296)
Excluding relapses in pregnancy
(n=363)
OR (CI), p OR (CI), p
1.95 (0.79,4.84), 0.147 1.33 (0.62,2.84), 0.463
2.03 (0.78,5.25), 0.147 1.50 (0.65,3.46), 0.338
1.48 (0.61,3.62), 0.385 1.22 (0.59,2.50), 0.587
1.47 (0.53,4.13), 0.459 0.97 (0.41,2.29), 0.946
1.53 (0.52,4.47), 0.438 1.06 (0.43,2.59), 0.906
1.20 (0.43,3.29), 0.728 0.94 (0.40,2.20), 0.886
d abuse, recency of last episode and smoking in pregnancy).
onths postpartum in women with history of serious mental illness,
Table 4
Random effects logistic regression analysis of association with medication exposure and relapse in the ﬁrst month postpartum.
All pregnancies Whole sample (n = 452) Excluding starters (n = 417) Excluding possible non-exposure (n = 447)
OR (CI), p OR (CI), p OR (CI), p
Unadjusted association 0.62 (0.30,1.27), 0.191 0.49 (0.23,1.04), 0.065 0.65 (0.33,1.28), 0.211
Model 1* 0.61 (0.29,1.28), 0.191 0.49 (0.23,1.04), 0.065 0.63 (0.31,1.28), 0.202
Model 2† 0.84 (0.41,1.72), 0.633 0.64 (0.31,1.33), 0.231 0.98 (0.52,1.84), 0.943
Model 2
affective group
0.74 (0.18,3.01), 0.670 0.70 (0.17,2.91), 0.624 0.74 (0.18,3.01), 0.670
Model 2
non-affective group
0.88 (0.41,1.92), 0.749 0.59 (0.25,1.38), 0.221 0.85 (0.39,1.86), 0.693
Excluding acute admissions in pregnancy
(n = 363) (n = 333) (n = 361)
Unadjusted 0.83 (0.35,1.98), 0.674 0.70 (0.29,1.69), 0.429 0.81 (0.34,1.95), 0.643
Model 1* 0.88 (0.36,2.16), 0.785 0.73 (0.30,1.79), 0.489 0.87 (0.35,2.12), 0.756
Model 2† 0.96 (0.41,2.22), 0.918 0.78 (0.33,1.80), 0.556 0.94 (0.41,2.19), 0.891
Model 2
Affective group
0.77 (0.16,3.81), 0.751
N = 190
0.55 (0.11,2.88), 0.479
N = 190
0.77 (0.16,3.81), 0.751
N = 190
Model 2
Non-affective group
1.10 (0.46,2.64), 0.827
N = 173
0.98 (0.42,2.32), 0.971
N = 173
1.06 (0.44,2.55), 0.892
N = 171
*Model 1: adjusted for age & ethnicity.
†Model 2: Model 1, plus factors associated at p b 0.2 in Table 1 (preterm birth, history of child abuse, recency of last episode and smoking in pregnancy).
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lapse than women with affective disorders. Although not statistically
signiﬁcant, again the study might have had insufﬁcient power to detect
what might be a clinically signiﬁcant difference. This study was initially
powered to detect an odds ratio of 3.5 for relapse in pregnancy in
women who discontinued versus those who continued medication in
a sample size of 205.
These ﬁndings support current recommendations that decisions
around medication in the perinatal period should involve a risk beneﬁt
analysis with attention to the likelihood of relapse based on individual
circumstances, illness severity and recency of acute episodes (Jones
et al., 2014). Clearlymore evidence is needed on risks and potential ben-
eﬁts of medication in late pregnancy.
4.3. Strengths and limitations
Amajor strength of our study is the novel case registerwhichhas en-
abled us to look at a larger sample ofwomen thanwould have been pos-
sible using a clinical study, while including clinical variables not
available in administrative data. We were able to include women who
may be too unwell to participate in clinical studies and our data is likely
to be free of the selection and recall bias of retrospective studies which
ascertain relapses by interview. Althoughwemight have incurred some
loss of data due to migration in this ethnically diverse population of
South London, the additional use of HES to determine admission to in-
patient care over thewhole of England has enabled us to account for pa-
tients moving into and out of the catchment area, reducing loss to
follow-up.
These data are likely generalisable to womenmanaged in secondary
care but we would not capture women managed in primary care who
may be less severely ill, which may account for the slightly elevated
rates particularly in the non-affective group in comparison with the
population registries. However, given that the risk of relapse is thought
to be at its highest in the early postpartum and the severe nature of
these disorders, it is likely that a large majority of women would be
managed in secondary care services at this time. The NICE guidelines
recommend that women who have history of SMI are referred to sec-
ondary mental health care in the perinatal period (NICE, 2014). We
were able to look at the whole heterogeneous spectrum of women
with SMI managed in secondary care. It would have been useful to be
able to determine the type of relapse and symptomswomenwith affec-
tive and non-affective SMI experienced. Use of HES enabled us to iden-
tify SLAM patients who delivered babies across the whole of England.Please cite this article as: Taylor, C.L., et al., Relapse in the ﬁrst three m
Schizophr. Res. (2018), https://doi.org/10.1016/j.schres.2018.07.037Home births are thought to be not well recorded in HES and these ac-
count for 2.4% of births in England in 2007 (ONS, 2013). Again,
women with SMI would be treated as high risk and therefore probably
less likely to have home births than the general population.
Detailed clinical data available in the patient notes enabled us to cap-
ture medication use including deﬁnitive information about stopping
and adherence, enabling us to reduce issues of misclassiﬁcation bias.
We were able to collect and adjust for information on many clinical
and socio-demographic factors, which previous research has found to
be associated with postpartum relapse. However, the CRIS data are not
collected for research and rely on the comprehensiveness of the clinical
notes which means that there is a strong likelihood of residual con-
founding due to information that is missing on variables such as
smoking, drug use and acute relapses in previous perinatal periods
which occurred more than 2 years before these index pregnancies.
4.4. Conclusions
This study conﬁrms a high risk of relapse in the early postpartumpe-
riod in women across the whole spectrum of SMI. However contrary to
our hypothesis, women with affective disorders were not statistically
more likely to relapse than women with non-affective disorders in
this study.We did ﬁnd that womenwith a recent relapsewere at higher
risk of postpartum relapse. Women with severe illnesses should be
warned pre-conception about the risk of relapse, particularly if they
have recently relapsed. Contrary to our hypothesis, women on nomed-
ication in the third trimester of pregnancy and/or early postpartum
were not at greater risk of postpartum relapse than women on regular
medication in the third trimester. The lack of (observational) evidence
onmedication prophylaxis heremaywell reﬂect confounding by indica-
tion and further research is needed on the risks and beneﬁts of the dif-
ferent types of medication used for SMI in the perinatal period.
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.schres.2018.07.037.
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